Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases

Xiaoli Zhang1,2, Yalei Zhao1,2, Liangru Liu1,2

  • 1Department of Infectious Diseases, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Current Drug Targets
|November 14, 2023
PubMed

Insights

Syndecan-1 (SDC-1) is crucial for liver cell functions and viral attachment. Shed SDC-1 plays roles in liver diseases, offering potential as a diagnostic and therapeutic target.

Area of Science:

  • Hepatology and Cell Biology
  • Molecular Medicine

Background:

  • Syndecan-1 (SDC-1) is a cell surface proteoglycan involved in growth factor signaling and cell adhesion.
  • In liver cells (hepatocytes), SDC-1 is vital for cellular functions and hepatitis virus attachment.
  • Shedding of SDC-1 during pathological conditions influences disease progression.

Approach:

  • This review synthesizes current research on Syndecan-1's role in liver diseases.
  • Mechanisms of SDC-1 involvement in liver disease pathogenesis are highlighted.
  • Potential diagnostic and therapeutic applications of SDC-1 are discussed.

Key Points:

  • SDC-1 regulates hepatocyte behavior and is implicated in liver diseases like fibrosis and cancer.
  • Shed SDC-1 can exert protective or detrimental effects in various pathologies.
  • SDC-1's role in hepatitis virus binding underscores its significance in liver infections.

Conclusions:

  • Syndecan-1 is a promising biomarker for diagnosing liver conditions.
  • Targeting SDC-1 presents a potential therapeutic strategy for liver diseases.
  • Further research into SDC-1 mechanisms can inform novel treatment approaches.